Araujo-Castro Marta, Parra Ramírez Paola, Robles Lázaro Cristina, García Centeno Rogelio, Gracia Gimeno Paola, Fernández-Ladreda Mariana Tomé, Sampedro Núñez Miguel Antonio, Marazuela Mónica, Escobar-Morreale Héctor F, Valderrabano Pablo
Department of Endocrinology & Nutrition, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), 28034 Madrid, Spain.
J Clin Med. 2021 Nov 25;10(23):5509. doi: 10.3390/jcm10235509.
To assess the risk of developing autonomous cortisol secretion (ACS) and tumour growth in non-functioning adrenal incidentalomas (NFAIs).
Multicentre retrospective observational study of patients with NFAIs. ACS was defined as serum cortisol >1.8 µg/dL after 1 mg-dexamethasone suppression test (DST) without specific data on Cushing's syndrome. Tumour growth was defined as an increase in maximum tumour diameter >20% from baseline; and of at least 5 mm.
Of 654 subjects with NFAIs included in the study, both tumour diameter and DST were re-evaluated during a follow-up longer than 12 months in 305 patients. After a median follow-up of 41.3 (IQR 24.7-63.1) months, 10.5% of NFAIs developed ACS. The risk for developing ACS was higher in patients with higher serum cortisol post-DST levels (HR 6.45 for each µg/dL, = 0.001) at diagnosis. Significant tumour growth was observed in 5.2% of cases. The risk of tumour growth was higher in females (HR 10.7, = 0.004).
The frequency of re-evaluation with DST in NFAIs during the initial 5 years from diagnosis can probably be tailored to the serum cortisol post-DST level at presentation. Re-evaluation of NFAIs with imaging studies, on the other hand, seems unnecessary in most cases, particularly if the initial imaging demonstrates features specific to typical adenoma, given the low rate of significant tumour growth.
评估无功能肾上腺偶发瘤(NFAIs)发生自主性皮质醇分泌(ACS)及肿瘤生长的风险。
对NFAIs患者进行多中心回顾性观察研究。ACS定义为在1mg地塞米松抑制试验(DST)后血清皮质醇>1.8µg/dL,且无库欣综合征的具体数据。肿瘤生长定义为最大肿瘤直径较基线增加>20%,且至少增加5mm。
研究纳入的654例NFAIs患者中,3个05例患者在超过12个月的随访期间重新评估了肿瘤直径和DST。中位随访41.3(IQR 24.7 - 63.1)个月后,10.5%的NFAIs发生了ACS。诊断时DST后血清皮质醇水平较高的患者发生ACS的风险更高(每µg/dL的HR为6.45,P = 0.001)。5.2%的病例观察到显著的肿瘤生长。女性肿瘤生长的风险更高(HR 10.7,P = 0.004)。
在诊断后的最初5年内,NFAIs患者DST复查的频率可能可以根据初诊时DST后的血清皮质醇水平进行调整。另一方面,在大多数情况下,对NFAIs进行影像学复查似乎没有必要,特别是如果初始影像学显示典型腺瘤的特征,因为显著肿瘤生长的发生率较低。